Neuraltus Pharmaceuticals Finds $17M
Menlo Park-based Neuraltus Pharmaceuticals, which is developing small molecule drugs for treating neurodegenerative diseases, said this morning that it has raised $17M in a Series A financing round. According to the firm, the funding came from Latterell Venture Partners, VantagePoint Venture Partners, and Adams Street Partners. Neuraltus said that Dr. James Woody of Latterrell, VantagePoint's Annette Bianchi, and Adams Street's Terry Gould have all joined the board along with the funding. The firm is developing treatments for Lou Gehrig's Disease (ALS), Parkinson's, and Gaucher's Disease; the funding will go towards Phase I and Phase II clinical trials.
posted on Thursday, March 26, 2009 (Link to more information)
Related companies:
Neuraltus Pharmaceuticals
Related stories:
> Arriva Pharmaceuticals Adds $6M
> MAP Pharmaceuticals Sets IPO Pricing
> Aldea Pharmaceuticals Takes $24M
> Alexza Pharmaceuticals Acquired By Ferrer
> Bridge Pharmaceuticals Raises $35M
silicontap.com Home